Medical information processing device

Abstract

To propose medical treatment in accordance with a patient's request.SOLUTION: A medical information processing apparatus according to the present embodiment comprises an acquisition unit, a control unit, and a presentation unit. The acquisition unit acquires gene therapy information associating candidate medicines that are therapeutic medicines for gene mutation related to a patient's disease, the effect of the candidate medicines, and incidental information on the candidate medicines with each other. The control unit determines the priority among the candidate medicines based on the gene therapy information and patient information on the patient. The presentation unit presents the priority in association with information representing the relevance between genes.SELECTED DRAWING: Figure 1

Description

Technical Field

[0001] The embodiments disclosed in this specification and the drawings relate to a medical information processing apparatus.

Background Art

[0002] For example, in a hospital, as a test result of a patient's gene, information on gene mutations related to the patient's disease is obtained to determine a therapeutic agent suitable for the patient. In this case, for example, a doctor operating a terminal in the hospital reads out the information stored in the gene database and determines therapeutic agents for gene mutations related to the patient's disease as candidate agents in descending order of therapeutic effect. Then, the doctor proposes the determined candidate agents to the patient as therapeutic agents suitable for the patient. However, when determining candidate agents considering only the therapeutic effect, there may be cases where treatment cannot be carried out with the candidate agents due to various circumstances of the patient.

Prior Art Documents

Patent Documents

[0003]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0004] One of the problems to be solved by the embodiments disclosed in this specification and the drawings is to propose treatment in line with the patient's desires. However, the problems solved by the embodiments disclosed in this specification and the drawings are not limited to the above problems. The problems corresponding to the respective effects of each configuration shown in the embodiments described later can also be regarded as other problems.

Means for Solving the Problems

[0005] The medical information processing device according to the present embodiment includes an acquisition unit, a control unit, and a presentation unit. The acquisition unit acquires gene therapy information that associates candidate drugs, which are therapeutic drugs for gene mutations associated with a patient's disease, with the effects of the candidate drugs and accompanying information of the candidate drugs. The control unit determines the priority order of the candidate drugs based on the gene therapy information and patient information related to the patient. The presentation unit presents the priority order in association with information indicating the relationship between genes. [Brief description of the drawings]

[0006]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5A

Figure 5B

Figure 5C

Figure 6

Figure 7

Figure 8

Figure 9

Embodiments for Carrying Out the Invention

[0007] Hereinafter, embodiments of a medical information processing apparatus will be described in detail with reference to the accompanying drawings. Hereinafter, a medical information processing system including the medical information processing apparatus will be described as an example. In the medical information processing system shown in FIG. 1, each apparatus is shown one by one, but actually, it can further include a plurality of apparatuses.

[0008] (First Embodiment) FIG. 1 is a diagram showing an example of the configuration of a medical information processing system including a medical information processing apparatus 100 according to the first embodiment. The medical information processing system shown in FIG. 1 includes a gene testing apparatus 200, a server 300, a terminal 50, and a medical information processing apparatus 100.

[0009] The gene testing apparatus 200 is an apparatus for testing a patient's genes. For example, the gene testing apparatus 200 acquires information on gene mutations related to the patient's disease from the patient's body fluid (blood or saliva) as the test result of the patient's genes, and transmits it to the medical information processing apparatus 100.

[0010] The server 300 includes a gene database 310. For example, the gene database 310 stores information including therapeutic agents for gene mutations related to diseases in a patient group and the effects of the therapeutic agents for each disease. For example, when there is a mutation of gene a in disease A, information including a therapeutic agent for the mutation of gene a in disease A and the effect of the therapeutic agent is stored in the gene database 310. When there is a mutation of gene a in disease B, information including a therapeutic agent for the mutation of gene a in disease B and the effect of the therapeutic agent is stored. Regarding the effect of the therapeutic agent, the content of the report from the hospital where the treatment was performed with the therapeutic agent and the content extracted from the literature on the therapeutic agent are registered in the gene database 310 as the effect of the therapeutic agent. The information stored in the gene database 310 can be read by the medical information processing apparatus 100.

[0011] The terminal 50 and the medical information processing device 100 are connected to, for example, a hospital internal LAN (Local Area Network) installed in the hospital, transmit information to a predetermined device, and receive information transmitted from a predetermined device. In addition, various servers such as an HIS (Hospital Information System) server are connected to the hospital internal LAN. Note that the HIS server may be connected to an external network in addition to the hospital internal LAN.

[0012] The terminal 50 is used by a doctor in the hospital. The terminal 50 includes, for example, a PC (Personal Computer), a tablet PC, a PDA (Personal Digital Assistant), a mobile terminal, and the like. A viewer (software) for displaying various information on its own display is installed in the terminal 50.

[0013] The medical information processing device 100 is a workstation for displaying various information on the display of the terminal 50. For example, an application (program) is implemented in the medical information processing device 100, and the application can be read by the terminal 50.

[0014] Hereinafter, details of the medical information processing device 100 according to the present embodiment will be described. FIG. 1 is a diagram showing an example of the configuration of the medical information processing device 100 according to the present embodiment. As shown in FIG. 1, the medical information processing device 100 includes an input interface 110, displays 120 and 123, a communication interface 130, a memory circuit 140, and a processing circuit 150.

[0015] The input interface 110 has a pointing device such as a mouse and a keyboard, etc., receives inputs of various operations on the medical information processing device 100 from the user, and transfers the instructions and setting information received from the user to the processing circuit 150. Here, the user is a medical staff including a doctor.

[0016] The display 120 is a monitor referred to by the user, and under the control of the processing circuit 150, it displays various data such as images to the user or displays a GUI (Graphical User Interface) for receiving various instructions and various settings from the user via the input interface 110. The communication interface 130 is an NIC (Network Interface Card) or the like and communicates with other devices.

[0017] The memory circuit 140 is, for example, a semiconductor memory element such as a RAM (Random Access Memory) or a flash memory, or a storage device such as a hard disk or an optical disk.

[0018] Furthermore, the memory circuit 140 stores a patient information DB 141, a gene test result DB 142, a gene mechanism information DB 143, and a gene therapy information DB 144 as various databases (hereinafter referred to as DBs) used by each processing function of the processing circuit 150 described later. The various DBs will be described later.

[0019] The processing circuit 150 controls the components of the medical information processing apparatus 100. For example, as shown in FIG. 1, the processing circuit 150 executes an acquisition function 151, a control function 152, and a presentation function 153. Here, for example, each processing function executed by the acquisition function 151, the control function 152, and the presentation function 153, which are components of the processing circuit 150, is recorded in the memory circuit 140 in the form of a program executable by a computer. The processing circuit 150 is a processor that reads each program from the memory circuit 140 and executes it to realize the functions corresponding to each program. In other words, the processing circuit 150 in the state of having read each program has each function shown in the processing circuit 150 of FIG. 1. Note that the acquisition function 151 is an example of an acquisition unit, the control function 152 is an example of a control unit, and the presentation function 153 is an example of a presentation unit.

[0020] In the above description, the term "processor" used means, for example, a circuit such as a CPU (Central Processing Unit), a GPU (Graphics Processing Unit), an application specific integrated circuit (ASIC), a programmable logic device (e.g., a simple programmable logic device (SPLD), a complex programmable logic device (CPLD), and a field programmable gate array (FPGA)). When the processor is, for example, a CPU, the processor realizes its function by reading and executing a program stored in the storage circuit 140. On the other hand, when the processor is, for example, an ASIC, instead of storing a program in the storage circuit 140, the program is directly incorporated into the circuit of the processor. Note that each processor of the present embodiment is not limited to being configured as a single circuit for each processor, and a plurality of independent circuits may be combined to be configured as one processor to realize its function. Further, a plurality of components in FIG. 1 may be integrated into one processor to realize its function.

[0021] As described above, the overall configuration of the medical information processing system including the medical information processing apparatus 100 according to the present embodiment has been described. Under such a configuration, the medical information processing apparatus 100 proposes a treatment that meets the patient's desires.

[0022] For example, in a hospital, as a test result of a patient's gene, information on gene mutations related to the patient's disease is obtained from the gene testing apparatus 200, and a therapeutic agent suitable for the patient is determined. In this case, for example, a doctor operating the terminal 50 reads information stored in the gene database 310 and determines therapeutic agents for gene mutations related to the patient's disease as candidate agents in descending order of treatment effect.

[0023] At this time, for example, the doctor refers to a screen on which the mechanism of action between genes, the gene on which the mutation has occurred, and the position where the candidate drug acts are presented together with the priority of each candidate drug on the gene map shown in the in-vivo information transmission pathway, and determines the therapeutic drug to be administered to the patient. Note that the gene map is a correlation diagram showing the relationship between genes and is an example of information representing the relationship between genes. Then, the doctor presents the determined candidate drug to the patient by displaying it on the display of the terminal 50. That is, the doctor proposes the determined candidate drug to the patient as a therapeutic drug suitable for the patient.

[0024] However, when determining candidate drugs considering only the therapeutic effect, there may be cases where treatment cannot be carried out with the candidate drugs due to various circumstances of the patient. For example, when the drug price of the candidate drug is high, there is a possibility that treatment cannot be carried out with the candidate drug due to circumstances such as the patient being unable to pay the treatment cost. Also, when the side effects of the candidate drug are undesirable for the patient, there is a possibility that the patient may give up continuing the treatment even if the administration of the candidate drug is started.

[0025] Therefore, the medical information processing apparatus 100 according to the present embodiment performs the following processing in order to propose treatment in line with the patient's desires. First, in the medical information processing apparatus 100 according to the present embodiment, the acquisition function 151 acquires gene therapy information that associates candidate drugs, which are therapeutic drugs for gene mutations related to the patient's disease, the effects of the candidate drugs, and the incidental information of the candidate drugs. The control function 152 determines the priority order of the candidate drugs based on the gene therapy information and the patient information regarding the patient. The presentation function 153 presents the priority order in association with the information representing the relationship between genes. Hereinafter, each process of the medical information processing apparatus 100 according to the first embodiment will be described in detail.

[0026] FIG. 2 is a diagram for explaining each processing function of the medical information processing apparatus 100 according to the first embodiment. FIG. 3 is a diagram showing an example of a gene map in the first embodiment. First, the process executed by the acquisition function 151 will be described with reference to FIGS. 2 and 3.

[0027] The acquisition function 151 stores patient information regarding the patient in the patient information DB 141. For example, a doctor operating the terminal 50 acquires patient information from the patient in advance by conducting a hearing or questionnaire on the patient, and the acquisition function 151 stores the acquired patient information in the patient information DB 141.

[0028] The patient information stored in the patient information DB 141 includes, for example, the patient's budget. Also, the patient information stored in the patient information DB 141 includes information regarding the insurance policy the patient is enrolled in. In this case, in the example shown in FIG. 2, it represents that the patient's budget is "50 (ten thousand yen)" and the patient's enrolled insurance is "Insurance A".

[0029] For example, the patient's gene is examined by the gene examination device 200. In this case, the acquisition function 151 acquires information on gene mutations related to the patient's disease from the gene examination device 200 as the examination result of the patient's gene, and stores the acquired information in the gene examination result DB 142 as the examination result of the patient's gene.

[0030] Based on the information stored in the gene database 310 and the information stored in the gene examination result DB 142, the acquisition function 151 acquires gene therapy information that associates a candidate drug, which is a therapeutic drug for gene mutations related to the patient's disease, the effect of the candidate drug, and the incidental information of the candidate drug, and stores the gene therapy information in the gene therapy information DB 144. In the example shown in FIG. 2, in the gene therapy information stored in the gene therapy information DB 144, it represents that the candidate drugs, which are the therapeutic drugs associated with the gene mutations found in the patient's examination results, are "Drug1", "Drug2", "Drug3", and the effects of the candidate drugs "Drug1", "Drug2", "Drug3" are represented by the numerical values of priority "2", "1", "3" respectively. Here, the higher the numerical value of the priority, the higher the effect of the candidate drug.

[0031] Note that the priority of the effect of each drug may be based on the information of the effect registered in the gene database 310, or may be calculated by the acquisition function 151 even if it is registered in the gene database 310.

[0032] The additional information of the candidate drug includes, for example, the drug price of the candidate drug. In this case, in the example shown in FIG. 2, it represents that the drug prices of the candidate drugs "Drug1", "Drug2", and "Drug3" are "100 (ten thousand yen)", "50 (ten thousand yen)", and "30 (ten thousand yen)", respectively.

[0033] In addition, the additional information includes, for example, information regarding insurance applicable to the candidate drug. Examples of insurance applicable to the candidate drug include insurance in the public medical insurance system and the insurance subscribed by the patient.

[0034] In this case, in the example shown in FIG. 2, the candidate drug "Drug1" can use insurance application in the public medical insurance system. For example, when the candidate drug "Drug1" is used as the patient's therapeutic drug, 30% of the drug price of the candidate drug "Drug1" is subsidized by the insurance application in the public medical insurance system with respect to the drug price of "100 (ten thousand yen)". That is, when the candidate drug "Drug1" is used as the patient's therapeutic drug, the amount to be paid by the patient is 100 (ten thousand yen) × 0.3 = 70 (ten thousand yen) due to the insurance application in the public medical insurance system.

[0035] Also, in the example shown in FIG. 2, the candidate drug "Drug2" can use "Insurance A" as the subscribed insurance. For example, when the candidate drug "Drug2" is used as the patient's therapeutic drug, 30% of the drug price of the candidate drug "Drug2" is subsidized by "Insurance A" with respect to the drug price of "50 (ten thousand yen)". That is, when the candidate drug "Drug2" is used as the patient's therapeutic drug, the amount to be paid by the patient is 50 (ten thousand yen) × 0.3 = 35 (ten thousand yen) due to the patient's subscribed insurance "Insurance A".

[0036] Furthermore, the additional information includes, for example, information on whether the candidate drug is an investigational drug or not, and further includes the cost required for the clinical trial if the candidate drug is an investigational drug. Here, an investigational drug is a new drug developed by a pharmaceutical company, and is administered to subjects such as patients at a hospital as part of a clinical trial conducted to obtain approval as a "drug" from a national institution (e.g., the Ministry of Health, Labor and Welfare). An investigational drug is also called a clinical trial drug. In the example shown in FIG. 2, the candidate drug "Drug3" is an investigational drug, and the cost required by the patient for the clinical trial is "100,000 yen." In this case, when the candidate drug "Drug3" is used as a therapeutic drug for the patient, the amount paid by the patient is 300,000 yen + 100,000 yen = 400,000 yen, taking into account the patient's clinical trial cost of "100,000 yen."

[0037] The acquisition function 151 also acquires a gene map 400, which is a correlation diagram showing the relationship between genes, based on the information stored in the gene database 310 and the information stored in the gene test result DB 142, and stores the acquired gene map 400 as gene mechanism information in the gene mechanism information DB 143. The gene map 400 is an example of information showing the relationship between genes. An enlarged view of the gene map 400 shown in FIG. 2 is shown in FIG. 3.

[0038] In the gene map 400 illustrated in FIG. 3, "GF," "DDD," "AAA," "BBB," and the like indicate biomolecules such as proteins that are produced by the expression of genes.

[0039] Figure 3 shows that the expression of the biomolecule "GF" promotes the expression of the biomolecule "MMM," ​​the biomolecule "MMM" promotes the expression of the biomolecule "NNN," and the biomolecule "NNN" promotes the expression of the biomolecule "OOO."

[0040] In addition, in FIG. 3, as an alternative pathway by the biomolecule "GF", it shows that the expression of the biomolecule "AAA" is promoted by the biomolecule "GF". Also, in FIG. 3, it shows that the biomolecule "AAA" is changed to the biomolecule "CCC" by the biomolecule "CCC", and the biomolecule "DDD" is changed to the biomolecule "AAA" by the biomolecule "BBB".

[0041] In addition, in FIG. 3, it shows that the expression of the biomolecule "EEE" is promoted by the biomolecule "DDD", and as a result, the survival of the cell is promoted. Also, in FIG. 3, it shows that the expression of the biomolecule "GGG" is suppressed by the biomolecule "FFF", and as a result, the growth of the cell is suppressed. Also, in FIG. 3, it shows that the expression of the biomolecule "QQQ" is suppressed by the biomolecule "FFF", and as a result, glycolysis is suppressed and the proliferation of the cell is suppressed.

[0042] In addition, in FIG. 3, when the cell is in a hypoxic state, the expression of the biomolecule "HHH" is promoted, the expression of the biomolecule "JJJ" is promoted by the biomolecule "HHH", the expression of the biomolecule "KKK" is promoted by the biomolecule "JJJ", the expression of the biomolecule "LLL" is promoted by the biomolecule "KKK", and as a result, the survival and proliferation of the cell are promoted. Also, in FIG. 3, it shows that the expression of the biomolecule "JJJ" and the biomolecule "KKK" are suppressed by the biomolecule "FFF", and the expression of the biomolecule "LLL" is suppressed by the biomolecule "PPP".

[0043] Note that in the above, the line with an arrow at the end was explained as expression promotion, but there may also be cases of function promotion. Also, in the above, the line with a circular arrow at the end was explained as expression suppression, but there may also be cases of function suppression.

[0044] And in FIG. 3, it is shown that a mutation has occurred in the gene encoding the biomolecule "BBB" according to the patient's genetic test results. Also, in FIG. 3, it represents that the copy number of the gene encoding the biomolecule "OOO" has increased according to the patient's genetic test results ("CNV (Copy Number Variation) gain"). Further, in FIG. 3, it represents that the copy number of the gene encoding the biomolecule "PPP" has decreased according to the patient's genetic test results ("CNV loss").

[0045] The above-mentioned candidate drugs "Drug1", "Drug2", and "Drug3" are, for example, therapeutic drugs for which a therapeutic effect has been confirmed for diseases caused by mutations in the gene encoding the biomolecule "BBB".

[0046] Next, with reference to FIG. 2, the process executed by the control function 152 will be described. The control function 152 determines the priority order of the candidate drugs based on the gene therapy information stored in the gene therapy information DB 144 and the patient information stored in the patient information DB 141.

[0047] In the example shown in FIG. 2, the effects of the candidate drugs "Drug1", "Drug2", and "Drug3" are the numerical values of priority "2", "1", and "3" respectively. When the candidate drugs "Drug1", "Drug2", and "Drug3" are used as the patient's therapeutic drugs, the payment amounts for the patient are 70 (ten thousand yen), 35 (ten thousand yen), and 40 (ten thousand yen) respectively. In this case, the control function 152 determines the priority order of the candidate drugs based on the effects of the candidate drugs "Drug1", "Drug2", and "Drug3" and the payment amount (cost) of the patient.

[0048] For example, among the candidate drugs "Drug1", "Drug2", and "Drug3", the candidate drug "Drug3" has the highest efficacy and the payment amount (400,000 yen) is within the patient's budget. Therefore, the priority of the candidate drug "Drug3" is ranked first. Also, the candidate drug "Drug2" has been shown to be effective and the payment amount (350,000 yen) is within the patient's budget. Therefore, the priority of the candidate drug "Drug2" is ranked second. The candidate drug "Drug1" has the second highest efficacy after "Drug3", but the payment amount is 700,000 yen, which is not within the patient's budget. Therefore, the priority of the candidate drug "Drug1" is ranked third.

[0049] The control function 152 generates support information 420 that associates the determined priority with the gene map 400 stored in the gene mechanism information DB 143.

[0050] Next, the process executed by the presentation function 153 will be described with reference to FIG. 2. The presentation function 153 presents to the doctor and the patient by displaying the support information 420 and the ranking table 430 indicating the priorities of the candidate drugs "Drug1", "Drug2", and "Drug3" on the display of the doctor's terminal 50.

[0051] For example, when the presentation function 153 displays the support information 420 on the display of the terminal 50, it presents the priority at the position where the candidate drug acts in the gene map 400. In this case, in the example shown in FIG. 2, at the position where the candidate drug "Drug3" acts in the gene map 400, for the biomolecule "LLL", "(1)", which indicates that the priority is first, is displayed. At the position where the candidate drug "Drug2" acts in the gene map 400, for the biomolecule "NNN", "(2)", which indicates that the priority is second, is displayed.

[0052] In addition, when the presentation function 153 displays the support information 420 on the display of the terminal 50, it presents the reasons for determining the priority order of the candidate drugs. Specifically, the presentation function 153 presents the priority order and reasons of the candidate drugs by displaying the comments 411 and 412 on the display of the terminal 50 in the gene map 400. In this case, in the example shown in FIG. 2, the comment 411 indicates the biomolecule "LLL" which is the position where the candidate drug "Drug3" acts in the gene map 400, and as the comment 411, "Priority 1: Drug3 has a high effect and is within the budget (40)" is displayed. Also, the comment 412 indicates the biomolecule "NNN" which is the position where the candidate drug "Drug2" acts in the gene map 400, and as the comment 412, "Priority 2: Drug2 has an observed effect and is within the budget (35)" is displayed.

[0053] Here, a specific example different from the process of FIG. 2 will be described with reference to FIG. 4. FIG. 4 is a diagram showing a process example different from the process example shown in FIG. 2.

[0054] As described above, the patient information stored in the patient information DB 141 includes the patient's budget and information regarding the insurance policy the patient is enrolled in. In this case, in the example shown in FIG. 4, it represents that the patient's budget is "50 (ten thousand yen)" and the patient's insurance policy is "Insurance A".

[0055] As described above, the gene therapy information stored in the gene therapy information DB 144 is information that associates candidate drugs, which are therapeutic drugs for gene mutations related to the patient's disease, the effects of the candidate drugs, and the incidental information of the candidate drugs. In this case, in the example shown in FIG. 4, it represents that the candidate drugs that are therapeutic drugs are "Drug1", "Drug2", "Drug3", "Drug4", "Drug5", and the effects of the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", "Drug5" are numerical values of priorities "1", "2", "3", "4", "5" respectively. Here, the higher the numerical value of the priority, the higher the effect of the candidate drug.

[0056] In gene therapy information, as described above, the supplementary information includes the drug price of the candidate drug, information regarding insurance applicable to the candidate drug, and information regarding clinical trials applicable to the candidate drug. Further, the supplementary information includes, for example, information indicating whether there is a generic drug for the candidate drug. In this case, in the example shown in FIG. 4, the drug prices of the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", and "Drug5" are represented as "200 (ten thousand yen)", "100 (ten thousand yen)", "50 (ten thousand yen)", "30 (ten thousand yen)", and "100 (ten thousand yen)", respectively. Also, there is a generic drug for the candidate drug "Drug1", and for example, the candidate drug "Drug2" is a generic drug of the candidate drug "Drug1". For example, the effect of the candidate drug "Drug2" is equivalent to the effect of the candidate drug "Drug1" or slightly higher than the effect of the candidate drug "Drug1". In the example shown in FIG. 4, the effect of the candidate drug "Drug2" is slightly higher than the effect of the candidate drug "Drug1".

[0057] Also, in the example shown in FIG. 4, when the candidate drugs "Drug1" and "Drug2" are used as the patient's therapeutic drugs, 70% of the drug price is subsidized by insurance application in the public medical insurance system with respect to the drug prices of the candidate drugs "Drug1" and "Drug2". When the candidate drug "Drug3" is used as the patient's therapeutic drug, 30% of the drug price is subsidized by "Insurance A" with respect to the drug price of the candidate drug "Drug3". Also, the candidate drug "Drug4" is a test drug, indicating that the cost required for the patient for the clinical trial is "10 (ten thousand yen)". Note that the clinical trial cost includes expenses such as transportation costs to the hospital when the location of the clinical trial is not the patient's regular hospital but another hospital.

[0058] The processing procedure will be described with reference to the example shown in FIG. 4. FIGS. 5A to 5C are flowcharts showing the processing procedure by the medical information processing apparatus 100 according to the first embodiment.

[0059] First, in step S101 of FIG. 5A, the acquisition function 151 acquires information on gene mutations related to the patient's disease. Specifically, the acquisition function 151 acquires, as the test result of the patient's gene, information on gene mutations related to the patient's disease from the gene testing device 200, and stores the acquired information in the gene test result DB142 as the test result of the patient's gene.

[0060] Next, in step S102 of FIG. 5A, the acquisition function 151 acquires a list of candidate therapeutic agents from the information stored in the gene database 310. Specifically, the acquisition function 151 acquires candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", "Drug5" that are therapeutic agents for the gene mutations related to the patient's disease based on the information stored in the gene database 310 and the information stored in the gene test result DB142.

[0061] Next, in step S103 of FIG. 5A, the acquisition function 151 acquires, based on the information stored in the gene database 310 and the information stored in the gene test result DB142, the effects of the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", "Drug5", and information such as the drug price, information on insurance applicable to the candidate drug, and information on clinical trials applicable to the candidate drug as additional information of the candidate drug. Then, the acquisition function 151 stores gene therapy information associating the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", "Drug5" with the effects of the candidate drugs and the additional information of the candidate drug in the gene therapy information DB144.

[0062] Next, in step S104 of FIG. 5A, the acquisition function 151 acquires the patient's budget "50 (ten thousand yen)" and "Insurance A", which is information on the insurance the patient is enrolled in, from the patient information stored in the patient information DB141.

[0063] Here, in step S105 of FIG. 5A, since the number of candidate drugs is 5, the control function 152 sets N = 5. When assuming that the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", and "Drug5" are n = 1, n = 2, n = 3, n = 4, and n = 5 respectively, currently, the count n is set to "0 (n = 0)".

[0064] In step S106 of FIG. 5B, the control function 152 checks whether each candidate drug is within the budget. In this case, the control function 152 increments the count n by 1 (n = n + 1) and executes the process of calculating the payment amount when the candidate drug "Drug1" is used as the patient's treatment drug. Specifically, when the candidate drug "Drug1" is used, in the example shown in FIG. 4, the candidate drug "Drug1" can use the insurance application in the public medical insurance system (step S107; Yes). Also, there is a generic drug for the candidate drug "Drug1" (step S108; Yes). In this case, the control function 152 calculates 100 (ten thousand yen) × 0.7 = 30 (ten thousand yen) as the payment amount when the generic drug "Drug2" of the candidate drug "Drug1" is applied for insurance by the public medical insurance system (step S109). Here, although not shown in the process flow of FIG. 5B, the control function 152 also calculates the payment amount when the candidate drug "Drug1" is applied for insurance by the public medical insurance system. In this case, the control function 152 calculates 200 (ten thousand yen) × 0.7 = 60 (ten thousand yen) as the payment amount when the candidate drug "Drug1" is applied for insurance by the public medical insurance system.

[0065] Note that when a candidate drug can use the insurance application in the public medical insurance system (step S107; Yes), but there is no generic drug for the candidate drug (step S108; No), the control function 152 calculates the payment amount when the candidate drug is applied for insurance by the public medical insurance system (step S110).

[0066] Here, since the current count n is "1 (n = 1)" instead of "5 (N = 5)" (step S117; No), the process executed by the control function 152 returns to step S106.

[0067] Next, the control function 152 increments the count n by 1 (step S106) and executes a process of calculating the payment amount when the candidate drug "Drug3" is used as the patient's therapeutic drug. Specifically, when the candidate drug "Drug3" is used, in the example shown in FIG. 4, the candidate drug "Drug3" cannot use the insurance application in the public medical insurance system (step S107; No), but the application of optional insurance is possible (step S111; Yes). Here, the patient has subscribed to "Insurance A" as the applicable optional insurance (step S112; Yes). In this case, the control function 152 calculates 50 (ten thousand yen) × 0.3 = 35 (ten thousand yen) as the payment amount when the patient's subscribed insurance "Insurance A" is applied to the candidate drug "Drug3" (step S113). Since the current count n is "3 (n = 3)" instead of "5 (N = 5)" (step S117; No), the process executed by the control function 152 returns to step S106.

[0068] Next, the control function 152 increments the count n by 1 (step S106) and executes a process of calculating the payment amount when the candidate drug "Drug4" is used as the patient's therapeutic agent. Specifically, when the candidate drug "Drug4" is used, in the example shown in FIG. 4, the candidate drug "Drug4" cannot use the insurance application in the public medical insurance system (step S107; No), and the application of optional insurance is not possible (step S111; No). Or, although the application of optional insurance is possible (step S111; Yes), the patient is not enrolled in the applicable optional insurance (step S112; No). Here, the candidate drug "Drug4" is an investigational drug, indicating that the cost required for the patient's clinical trial is "10 (ten thousand yen)" (step S114; Yes). In this case, the control function 152 calculates 30 (ten thousand yen) + 10 (ten thousand yen) = 40 (ten thousand yen) as the payment amount including the patient's clinical trial cost "10 (ten thousand yen)" for the candidate drug "Drug4" (step S115). Since the current count n is "4 (n = 4)" instead of "5 (N = 5)" (step S117; No), the process executed by the control function 152 returns to step S106.

[0069] Next, the control function 152 increments the count n by 1 (step S106) and executes a process of calculating the payment amount when the candidate drug "Drug5" is used as the patient's therapeutic agent. Specifically, when the candidate drug "Drug5" is used, in the example shown in FIG. 4, the candidate drug "Drug5" cannot use the insurance application in the public medical insurance system (step S107; No), and the application of optional insurance is not possible (step S111; No). Also, it is assumed that the patient is not conducting a clinical trial (step S114; No). In this case, the control function 152 calculates the payment amount for the patient as 100 (ten thousand yen) for the candidate drug "Drug5" (step S115). Since the current count n is "5 (N = 5)" (step S117; Yes), the process executed by the control function 152 ends.

[0070] Note that the processing flow shown in FIG. 5B is an example, and the order and content of the processing flow executed by the control function 152 are not limited to this. For example, in the processing flow shown in FIG. 5B, when a generic drug exists for a candidate drug, the payment amount when insurance is applied under the public medical insurance system is calculated for the generic drug. However, when a generic drug exists for a candidate drug, the payment amount when insurance is applied under the public medical insurance system may be calculated for both the candidate drug and the generic drug of the candidate drug. Also, the ratio at which the drug price is subsidized by insurance application in the public medical insurance system is the same for the candidate drug and the generic drug of the candidate drug, but it may be different.

[0071] Next, in step S118 of FIG. 5C, the control function 152 increases the priority of the candidate drugs that fit within the patient's budget and ranks the priorities. In the example shown in FIG. 4, the effects of the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", "Drug5" are the numerical values of priorities "1", "2", "3", "4", "5" respectively. When the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", "Drug5" are used as the patient's therapeutic drugs, the patient's payment amounts are 30 (ten thousand yen), 60 (ten thousand yen), 35 (ten thousand yen), 40 (ten thousand yen), 100 (ten thousand yen) respectively. In this case, the control function 152 determines the priority order of the candidate drugs based on the effects of the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", "Drug5" and the patient's payment amount (cost).

[0072] In this case, in the example shown in FIG. 4, since the candidate drug "Drug4" has a higher effect than the candidate drug "Drug5" and the payment amount (400,000 yen) is within the patient's budget, the priority of the candidate drug "Drug4" is raised from "4" to "5", and the priority order of the candidate drug "Drug4" becomes the first. Also, since the candidate drug "Drug3" has a higher effect than the candidate drug "Drug4" and the payment amount (350,000 yen) is within the patient's budget, the priority of the candidate drug "Drug3" is raised from "3" to "4", and the priority order of the candidate drug "Drug3" becomes the second. Also, since the candidate drug "Drug2" has a higher effect than the candidate drug "Drug3" and the payment amount (300,000 yen) is within the patient's budget, the priority of the candidate drug "Drug2" is raised from "1" to "3", and the priority order of the candidate drug "Drug2" becomes the third. Also, although the candidate drug "Drug5" has the highest effect, the payment amount is 1,000,000 yen and it is not within the patient's budget, so the priority of the candidate drug "Drug5" is lowered from "5" to "2", and the priority order of the candidate drug "Drug5" becomes the fourth. Also, although the candidate drug "Drug1" has a higher effect than the candidate drug "Drug2", the payment amount is 600,000 yen and it is not within the patient's budget, so the priority of the candidate drug "Drug1" remains "1", and the priority order of the candidate drug "Drug1" becomes the fifth.

[0073] Next, in step S119 of FIG. 5C, the control function 152 generates support information 420 including the determined priority order. Specifically, the control function 152 generates support information 420 in which the determined priority order is associated with the gene map 400 stored in the gene mechanism information DB143.

[0074] Next, in step S120 of FIG. 5C, the presentation function 153 presents the priority order to the doctor and the patient by displaying it on the display of the doctor's terminal 50. Specifically, the presentation function 153 presents the support information 420 and the ranking table 430 showing the priority order of the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", and "Drug5" to the doctor and the patient.

[0075] Next, in step S121 of FIG. 5C, the presentation function 153 displays the reason why the priority has been changed from the priority based only on the effect in the support information 420 or the ranking table 430, which is a table of priority. Specifically, the presentation function 153 displays the first to third comments in the gene map 400 on the display of the terminal 50, thereby presenting the priority order and the reason for the candidate drug. For example, the first comment indicates the position where the candidate drug "Drug4" acts in the gene map 400, and the comment "Priority 1: Drug4, highly effective, within budget (40)" is displayed. The second comment indicates the position where the candidate drug "Drug3" acts in the gene map 400, and the comment "Priority 2: Drug3, second most effective after Drug4, within budget (35)" is displayed. The third comment indicates the position where the candidate drug "Drug2" acts in the gene map 400, and the comment reads, "Priority 3: Drug2 is the second most effective after Drug3, and is within budget (30)." Here, the third comment further indicates that the candidate drug "Drug2" is a generic drug of the candidate drug "Drug1."

[0076] As described above, in the medical information processing apparatus 100 according to the first embodiment, the acquisition function 151 acquires gene therapy information that associates candidate drugs, which are therapeutic drugs for gene mutations related to a patient's disease, with the effects of the candidate drugs and the associated information of the candidate drugs. Then, the control function 152 determines the priority of the candidate drugs based on the gene therapy information and the patient information related to the patient, and the presentation function 153 presents the priority in association with information indicating the relationship between genes. In this way, the medical information processing apparatus 100 according to the first embodiment presents the priority of the candidate drugs that takes into account not only the therapeutic effects but also the patient's budget and information on the insurance to which the patient is subscribed as patient information stored in the patient information DB 141, so that the patient can select a candidate drug according to his / her wishes. Therefore, in the medical information processing apparatus 100 according to the first embodiment, treatment can be performed with a candidate drug according to the patient's wishes, so that treatment according to the patient's wishes can be proposed.

[0077] (Second Embodiment) In the first embodiment, the case of determining the priority of candidate drugs according to the patient's budget has been described. However, the embodiments are not limited thereto. In the second embodiment, the case of determining the priority of candidate drugs according to the living level desired by the patient will be described. Specifically, in the second embodiment, the patient information stored in the patient information DB 141 is information regarding the living level desired by the patient. For example, although the patient may be restricted from physically strenuous activities by the implementation of treatment, the patient hopes to be able to walk and perform light work. Suppose the side effect of the first candidate drug is "able to walk but unable to work", and the side effect of the second candidate drug is "able to perform the same daily life as before the onset without restrictions". In this case, the control function 152 determines the priority of the candidate drugs by setting the priority of the second candidate drug higher than that of the first candidate drug and ranking the priorities, and the presentation function 153 presents the priorities in association with the information representing the relevance between genes.

[0078] FIG. 6 is a diagram showing the processing by the medical information processing apparatus 100 according to the second embodiment.

[0079] For example, the patient information stored in the patient information DB 141 includes information regarding the living level desired by the patient as described above. In the example shown in FIG. 6, in the case where the patient is currently living a life where "the same daily life as before the onset can be performed without restrictions", the current living level of the patient is represented as "0", and when the patient hopes to live a life where "physically strenuous activities are restricted but walking is possible and light work is possible" due to the implementation of treatment, the living level desired by the patient is represented as "1".

[0080] For example, the gene therapy information stored in the gene therapy information DB 144 is information that associates a candidate drug, which is a therapeutic agent for a gene mutation related to a patient's disease, the effect of the candidate drug, and the supplementary information of the candidate drug. In this case, in the example shown in FIG. 6, it is shown that the candidate drugs that are therapeutic agents are "Drug1", "Drug2", "Drug3", "Drug4", and "Drug5", and the effects of the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", and "Drug5" are represented by numerical values of priority "1", "2", "3", "4", and "5", respectively. Here, the higher the numerical value of the priority, the higher the effect of the candidate drug.

[0081] In gene therapy information, as described above, the supplementary information includes information on the side effects of the candidate drug. In this case, in the example shown in FIG. 6, it is shown that the side effects of the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", and "Drug5" are "none", "abdominal pain, loose stools", "vomiting", "fever of 38 degrees or higher", and "severe vomiting, fever of 38 degrees or higher", respectively.

[0082] Also, in the example shown in FIG. 6, when the side effect of the candidate drug "Drug1" is "none", since the patient's life can be "the same daily life as before the onset without any restrictions", the side effect level is represented as "0". Also, when the side effect of the candidate drug "Drug2" is "abdominal pain, loose stools", since the patient's life is "physically strenuous activities are restricted but walking is possible and light work is possible", the side effect level is represented as "1". Also, when the side effect of the candidate drug "Drug3" is "vomiting", since the patient's life is "walking is possible but work cannot be done", the side effect level is represented as "2". Also, when the side effect of the candidate drug "Drug4" is "fever of 38 degrees or higher", since the patient's life is "only able to do things around oneself with limitations", the side effect level is represented as "3". Also, when the side effect of the candidate drug "Drug5" is "fever of 38 degrees or higher", since the patient's life is "severe vomiting, fever of 38 degrees or higher", the side effect level is represented as "4".

[0083] Therefore, based on the gene therapy information stored in the gene therapy information DB 144 and the patient information stored in the patient information DB 141, the control function 152 determines the priority order of the candidate drugs. Specifically, the control function 152 determines the priority order of the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", "Drug5" based on the side effects and side effect levels of these candidate drugs and the living level desired by the patient.

[0084] For example, for the candidate drugs "Drug3", "Drug4", "Drug5", although the effects of these candidate drugs are high, the side effect levels of these candidate drugs are at the living level "1" desired by the patient, and the patient cannot lead a life where "strenuous physical activities are restricted but walking is possible and light work is possible". For the candidate drugs "Drug1", "Drug2", although the effects of these candidate drugs are low, the side effect levels of these candidate drugs are at the living level "1" desired by the patient, and the patient can lead a life where "strenuous physical activities are restricted but walking is possible and light work is possible".

[0085] Here, when either of the candidate drugs "Drug1" or "Drug2" is used as the patient's therapeutic drug, since the effect of the candidate drug "Drug2" is higher than that of the candidate drug "Drug1", the priority order of the candidate drug "Drug2" is 1st, and the priority order of the candidate drug "Drug1" is 2nd. Also, when any of the candidate drugs "Drug3", "Drug4", "Drug5" is used as the patient's therapeutic drug, in order of high effect, the priority order of the candidate drug "Drug5" is 3rd, the priority order of the candidate drug "Drug4" is 4th, and the priority order of the candidate drug "Drug3" is 5th.

[0086] In this case, the control function 152 generates support information 420 that associates the determined priority order with the gene map 400 stored in the gene mechanism information DB 143. Then, the presentation function 153 presents the support information 420 and the ranking table 430 representing the priority order of the candidate drugs "Drug1", "Drug2", "Drug3", "Drug4", and "Drug5" to the doctor and the patient by displaying them on the display of the doctor's terminal 50.

[0087] For example, when the presentation function 153 displays the support information 420 on the display of the terminal 50, it presents the priority order at the position where the candidate drug acts in the gene map 400. In this case, in the example shown in FIG. 6, at the position where the candidate drug "Drug2" acts in the gene map 400, "(1)", which indicates that the priority order is 1, is displayed, and at the position where the candidate drug "Drug1" acts in the gene map 400, "(2)", which indicates that the priority order is 2, is displayed.

[0088] In addition, when the presentation function 153 displays the support information 420 on the display of the terminal 50, it presents the reason for determining the priority order of the candidate drug. Specifically, the presentation function 153 presents the priority order and the reason of the candidate drug by displaying the first and second comments on the display of the terminal 50 in the gene map 400. In this case, in the example shown in FIG. 6, the first comment points to the position where the candidate drug "Drug2" acts in the gene map 400, and as the first comment, "Priority 1: Drug2 High priority (effect and quality of life)" is displayed. The second comment points to the position where the candidate drug "Drug1" acts in the gene map 400, and as the second comment, "Priority 2: Drug1 Next highest priority (effect and quality of life)" is displayed.

[0089] In this way, the medical information processing apparatus 100 according to the second embodiment presents the priority order of candidate drugs considering not only the treatment effect but also information regarding the desired living level of the patient as patient information. As a result, the patient can select candidate drugs that meet their desires. For this reason, in the medical information processing apparatus 100 according to the second embodiment, since treatment can be performed using candidate drugs that meet the patient's desires, it is possible to propose treatment that meets the patient's requests.

[0090] Note that in the medical information processing apparatus 100 according to the second embodiment, as patient information stored in the patient information DB 141, the living level desired by the patient is cited, and as the living level, the side effects of the candidate drugs are cited as an example, but it is not limited thereto. The living level desired by the patient may also be the administration method of the candidate drugs. In this case, in the gene therapy information stored in the gene therapy information DB 144, the additional information includes information regarding the administration method of the candidate drugs. For example, assume that the patient hopes to be able to perform the same daily life as before the onset, the administration method of the first candidate drug is "prescription implemented once every two weeks at an outpatient clinic", and the administration method of the second candidate drug is "continuous intravenous drip for one week in the hospital". In this case, the control function 152 determines the priority order of the candidate drugs by setting the priority of the second candidate drug higher than that of the first candidate drug and ranking the priorities, and the presentation function 153 presents the priorities in association with the information representing the relevance between the genes.

[0091] In addition, in the medical information processing apparatus 100 according to the second embodiment, the patient information stored in the patient information DB 141 includes the living level desired by the patient. In addition to the patient's budget and information regarding the insurance policy the patient subscribes to, the patient information may also include the living level desired by the patient. For example, if within the budget, the patient may desire that strenuous physical activities may be restricted even after treatment. Although the first candidate drug is within the budget, the side effect of the first candidate drug is "able to walk but unable to work", and the side effect of the second candidate drug is "able to carry out daily life without restrictions as before the onset of the disease", but the second candidate drug is not within the budget. In this case, the control function 152 determines the priority order of the candidate drugs by setting the priority of the first candidate drug higher than that of the second candidate drug and ranking the priorities, and the presentation function 153 presents the priorities in association with the information representing the relationship between genes.

[0092] In addition, in the medical information processing apparatus 100 according to the first and second embodiments, the patient information stored in the patient information DB 141 may further include the patient's medication history. In this case, in the gene therapy information stored in the gene therapy information DB 144, the additional information includes information regarding the components included in the candidate drugs. For example, if there is information indicating the cumulative toxicity of platinum in the candidate drug, the acquisition function 151 acquires the cumulative amount of platinum from the patient's medication history. Information such as the patient's medication history is acquired from the HIS server as, for example, information in the electronic medical record. If the amount that can be ingested throughout life exceeds the amount that can be administered by the candidate drug, the control function 152 lowers the priority order of that candidate drug.

[0093] (Third Embodiment) In the medical information processing apparatus 100 according to the third embodiment, the control function 152 receives a change in patient information from the doctor's terminal 50, and based on the information for which the change has been received, re-determines the priority order of candidate drugs. For example, when the patient information stored in the patient information DB 141 changes in terms of the patient's budget, when newly subscribing to optional insurance, or when the desired living level changes, the acquisition function 151 updates the patient information. Also, in the gene therapy information stored in the gene therapy information DB 144, when there is a change in the drug price of the drug, the applicability of insurance, or the status of the implementation of a clinical trial as additional information, the acquisition function 151 updates the additional information.

[0094] FIG. 7 is a diagram showing the processing by the medical information processing apparatus 100 according to the third embodiment.

[0095] For example, the patient information stored in the patient information DB 141 includes the patient's budget and information regarding the insurance the patient is subscribed to. In this case, in the example shown in FIG. 7, it represents that the patient's budget is "30 (ten thousand yen)" and the patient's subscribed insurance is "Insurance A".

[0096] For example, the gene therapy information stored in the gene therapy information DB 144 is information that associates candidate drugs, which are therapeutic drugs for gene mutations related to the patient's disease, the effects of the candidate drugs, and the additional information of the candidate drugs. In this case, in the example shown in FIG. 7, it represents that the candidate drugs, which are therapeutic drugs, are "Drug1", "Drug2", and "Drug3", and the effects of the candidate drugs "Drug1", "Drug2", and "Drug3" are represented by numerical values of priority levels "1", "2", and "3", respectively. Here, the higher the numerical value of the priority level, the higher the effect of the candidate drug.

[0097] In the gene therapy information, the additional information includes the drug price of the candidate drug, information regarding the insurance applicable to the candidate drug, and information regarding the clinical trial applicable to the candidate drug. In this case, in the example shown in FIG. 7, it represents that the drug prices of the candidate drugs "Drug1", "Drug2", and "Drug3" are "100 (ten thousand yen)", "50 (ten thousand yen)", and "30 (ten thousand yen)", respectively.

[0098] Also, in the example shown in FIG. 7, when candidate drugs "Drug1" and "Drug2" are used as the patient's therapeutic agents, 70% of the drug price of candidate drug "Drug1" is subsidized by insurance application in the public medical insurance system. When candidate drug "Drug2" is used as the patient's therapeutic agent, 30% of the drug price of candidate drug "Drug2" is subsidized by "Insurance A". Also, candidate drug "Drug3" is an investigational drug, indicating that the cost for the patient to participate in the trial is "100,000 yen". Note that the trial cost includes expenses such as transportation costs to that hospital when the trial is conducted at a hospital other than the patient's regular hospital.

[0099] In this case, candidate drug "Drug1" has the lowest efficacy among candidate drugs "Drug1", "Drug2", and "Drug3", but the payment amount (300,000 yen) is within the patient's budget, so the priority of this candidate drug "Drug1" is No. 1. Also, candidate drug "Drug2" has a payment amount (350,000 yen) that is not within the patient's budget, but it is the second most effective after candidate drug "Drug1", so the priority of this candidate drug "Drug2" is No. 2. Candidate drug "Drug3" has the highest efficacy among candidate drugs "Drug1", "Drug2", and "Drug3", but the payment amount (400,000 yen) is not within the patient's budget, so the priority of this candidate drug "Drug3" is No. 3.

[0100] Here, assume that the patient's budget has changed as the patient information stored in the patient information DB141. For example, as shown in (1) of FIG. 7, assume that the patient's budget has been changed from "300,000 yen" to "500,000 yen". The control function 152 re-determines the priority of the candidate drugs based on the changed patient budget.

[0101] For example, as shown in (2) of FIG. 7, among the candidate drugs "Drug1", "Drug2", and "Drug3", the candidate drug "Drug3" has the highest efficacy and the payment amount (400,000 yen) is within the patient's budget. Therefore, the priority of the candidate drug "Drug3" is ranked first. Also, the candidate drug "Drug2" has the second highest efficacy after the candidate drug "Drug3" and the payment amount (350,000 yen) is within the patient's budget. Therefore, the priority of the candidate drug "Drug2" is ranked second. The candidate drug "Drug1" has the second highest efficacy after "Drug2" and the payment amount (300,000 yen) is within the patient's budget. Therefore, the priority of the candidate drug "Drug1" is ranked third.

[0102] In this case, the control function 152 generates support information 420 that associates the determined priority with the gene map 400 stored in the gene mechanism information DB 143. Then, the presentation function 153 presents the support information 420 and a ranking table 430 representing the priorities of the candidate drugs "Drug1", "Drug2", and "Drug3" to the doctor and the patient by displaying them on the display of the doctor's terminal 50. For example, as shown in (3) of FIG. 7, the presentation function 153 presents the ranking table 430 representing the priorities of the candidate drugs "Drug1", "Drug2", and "Drug3" to the doctor and the patient.

[0103] For example, when the presentation function 153 displays the support information 420 on the display of the terminal 50, it presents the priority at the position where the candidate drug acts in the gene map 400. In the example shown in FIG. 7, in this case, at the position where the candidate drug "Drug3" acts in the gene map 400, "(1)", which indicates that the priority is first, is displayed, and at the position where the candidate drug "Drug2" acts in the gene map 400, "(2)", which indicates that the priority is second, is displayed.

[0104] In addition, when the presentation function 153 displays the support information 420 on the display of the terminal 50, it presents the reason for determining the priority order of the candidate drugs. Specifically, the presentation function 153 presents the priority order and reason of the candidate drugs by causing the first and second comments in the gene map 400 to be displayed on the display of the terminal 50. In this case, in the example shown in FIG. 7, the first comment indicates the position where the candidate drug "Drug3" acts in the gene map 400, and as the first comment, "Priority 1: Drug3 has a high effect and is within the budget (40)" is displayed. The second comment indicates the position where the candidate drug "Drug2" acts in the gene map 400, and as the second comment, "Priority 2: Drug2 has the next highest effect and is within the budget (35)" is displayed.

[0105] As described above, the medical information processing apparatus 100 according to the third embodiment receives a change in patient information, and based on the information for which the change has been received, re-determines the priority order of the candidate drugs, so that the patient can select a candidate drug that meets their wishes. Therefore, in the medical information processing apparatus 100 according to the third embodiment, since treatment can be performed with a candidate drug that meets the patient's wishes, it is possible to propose a treatment that meets the patient's request.

[0106] (Fourth Embodiment) For example, in the medical information processing apparatus 100 according to the fourth embodiment, in the gene therapy information stored in the gene therapy information DB 144, the additional information further includes an adoption rate representing the ratio at which the candidate drug has been adopted. In this case, the control function 152 further determines the priority order of the candidate drugs based on the adoption rate of the candidate drugs.

[0107] FIGS. 8 and 9 are diagrams showing the processing by the medical information processing apparatus 100 according to the fourth embodiment.

[0108] In the medical information processing apparatus 100 according to the fourth embodiment, the changes from the third embodiment will be described. In this case, as shown in FIG. 8(1), the candidate drug "Drug3" is the most effective among the candidate drugs "Drug1", "Drug2", and "Drug3", and the payment amount (400,000 yen) is within the patient's budget. Therefore, the priority of the candidate drug "Drug3" is the first. Also, the candidate drug "Drug2" is the second most effective after the candidate drug "Drug3", and the payment amount (350,000 yen) is within the patient's budget. Therefore, the priority of the candidate drug "Drug2" is the second. The candidate drug "Drug1" is the second most effective after "Drug2", and the payment amount (300,000 yen) is within the patient's budget. Therefore, the priority of the candidate drug "Drug1" is the third.

[0109] Also, in the example shown in FIG. 8, in the gene therapy information, the additional information further includes an adoption rate representing the ratio of the candidate drug adopted. The adoption rate is determined based on the frequency of the candidate drug being selected. For example, the control function 152 receives the candidate drug selected by each patient from the doctor's terminal 50, and determines the adoption rate of the candidate drug based on the received candidate drug. That is, the adoption rate of the candidate drug is updated each time the candidate drug is selected.

[0110] For example, as shown in FIG. 8(2), the updated information is fed back to the gene therapy information DB 144. As shown in FIG. 8(3), the adoption rates of the candidate drugs "Drug1", "Drug2", and "Drug3" are updated to "20%", "50%", and "30%", respectively. In this case, as shown in FIG. 8(4), the control function 152 further determines the priority of the candidate drug based on the adoption rate of the candidate drug as the gene therapy information stored in the gene therapy information DB 144.

[0111] As shown in FIG. 9, the control function 152 calculates the effect (priority) of a candidate drug by effect × adoption rate / payment amount. For example, for the candidate drug "Drug1", if the effect (priority) is represented by "1", the payment amount is 30 (ten thousand yen), and the adoption rate is "20%", then the effect (priority) of the candidate drug "Drug1" considering the adoption rate is calculated as 1 × 20 / 30 = 0.66. Also, for the candidate drug "Drug2", if the effect (priority) is represented by "2", the payment amount is 35 (ten thousand yen), and the adoption rate is "50%", then the effect (priority) of the candidate drug "Drug2" considering the adoption rate is calculated as 2 × 50 / 35 = 2.85. Further, for the candidate drug "Drug3", if the effect (priority) is represented by "3", the payment amount is 40 (ten thousand yen), and the adoption rate is "30%", then the effect (priority) of the candidate drug "Drug3" considering the adoption rate is calculated as 3 × 30 / 40 = 2.25.

[0112] In this case, among the candidate drugs "Drug1", "Drug2", and "Drug3", the candidate drug "Drug2" has the highest priority, so the priority rank of the candidate drug "Drug2" is 1. Also, since the candidate drug "Drug1" has the second-highest priority after "Drug2", the priority rank of the candidate drug "Drug1" is 2. The candidate drug "Drug3" has the second-highest priority after "Drug1", so the priority rank of the candidate drug "Drug3" is 3.

[0113] Therefore, the control function 152 generates support information 420 that associates the determined priority ranks with the gene map 400 stored in the gene mechanism information DB 143. Then, the presentation function 153 presents to the doctor and the patient by displaying the support information 420 and a ranking table 430 representing the priority ranks of the candidate drugs "Drug1", "Drug2", and "Drug3" on the display of the doctor's terminal 50. For example, as shown in (5) of FIG. 8, the presentation function 153 presents the ranking table 430 representing the priority ranks of the candidate drugs "Drug1", "Drug2", and "Drug3" to the doctor and the patient.

[0114] For example, when the presentation function 153 displays the support information 420 on the display of the terminal 50, it presents the priority at the position where the candidate drug acts in the gene map 400. In this case, in the example shown in FIG. 8, at the position where the candidate drug "Drug2" acts in the gene map 400, "(1)", which represents that the priority is No. 1, is displayed, and at the position where the candidate drug "Drug3" acts in the gene map 400, "(2)", which represents that the priority is No. 2, is displayed.

[0115] In addition, when the presentation function 153 displays the support information 420 on the display of the terminal 50, it presents the reason for determining the priority of the candidate drug. Specifically, the presentation function 153 presents the priority and the reason of the candidate drug by displaying the first and second comments on the display of the terminal 50 in the gene map 400. In this case, in the example shown in FIG. 8, the first comment indicates the position where the candidate drug "Drug2" acts in the gene map 400, and as the first comment, "Priority 1: Drug2 High priority (effect and adoption rate), within budget (35)" is displayed. The second comment indicates the position where the candidate drug "Drug3" acts in the gene map 400, and as the second comment, "Priority 2: Drug3 Next highest priority (effect and adoption rate), within budget (40)" is displayed.

[0116] As described above, the medical information processing apparatus 100 according to the fourth embodiment further determines the priority of the candidate drug based on the adoption rate representing the ratio of the candidate drug that has been adopted, so that the patient can select a candidate drug that meets the requirements. Therefore, in the medical information processing apparatus 100 according to the fourth embodiment, since treatment can be performed with a candidate drug that meets the patient's wishes, a treatment that meets the patient's desires can be proposed.

[0117] Note that the adoption rate is determined based on, but not limited to, the frequency with which a candidate drug is selected. For example, the adoption rate is determined based on the frequency with which a candidate drug is selected and new findings regarding the candidate drug. For example, the control function 152 receives candidate drugs selected by each patient from the doctor's terminal 50, and determines the adoption rate of the received candidate drug. That is, the adoption rate of a candidate drug is determined based on the frequency with which the candidate drug is selected and new findings regarding the candidate drug.

[0118] For example, as new findings regarding a candidate drug, information such as candidate drugs that were selected in the past with a budget similar to the patient's budget and candidate drugs that were adopted under the conditions of insurance coverage is included.

[0119] Specifically, for example, if the candidate drugs that were selected in the past with a budget similar to the patient's budget are the first and second candidate drugs, and as a result of calculating the effects (priorities) of the first and second candidate drugs in consideration of the adoption rate, the priority of the first candidate drug is higher than that of the second candidate drug. In this case, the control function 152 determines the priority order of the candidate drugs by making the priority of the first candidate drug higher than that of the second candidate drug and ranking the priorities, and the presentation function 153 presents the priority order in association with the information representing the relevance between genes.

[0120] Similarly, if the candidate drugs that were adopted under the conditions of insurance coverage are the first and second candidate drugs, and as a result of calculating the effects (priorities) of the first and second candidate drugs in consideration of the adoption rate, the priority of the first candidate drug is higher than that of the second candidate drug. In this case, the control function 152 determines the priority order of the candidate drugs by making the priority of the first candidate drug higher than that of the second candidate drug and ranking the priorities, and the presentation function 153 presents the priority order in association with the information representing the relevance between genes.

[0121] For example, as new findings regarding a candidate drug, information regarding the side effects of the candidate drug is included.

[0122] Specifically, for example, assume that the candidate drugs are the first and second candidate drugs, and as a result of calculating the effects (priorities) of the first and second candidate drugs in consideration of the adoption rates, the priority of the first candidate drug is higher than that of the second candidate drug. However, it is stated that there are side effects when using the first candidate drug for gene mutation Z, but according to past results, side effects occur only in patients having both gene mutations Z and Y. On the other hand, it is assumed that there are no side effects when using the first candidate drug for patients having only gene mutation Z or patients having gene mutations Z and X. For example, when the patient to be treated has gene mutations Z and X, the control function 152 determines the priority order of the candidate drugs by making the priority of the second candidate drug higher than that of the first candidate drug and ranking the priorities, and the presentation function 153 presents the priority order in association with the information representing the inter-gene relevance.

[0123] Also, for example, assume that the candidate drugs are the first and second candidate drugs, and as a result of calculating the effects (priorities) of the first and second candidate drugs in consideration of the adoption rates, the priority of the second candidate drug is higher than that of the first candidate drug. However, although it is stated in, for example, literature that there are no side effects when using the second candidate drug, assume that there are cases where side effects have occurred according to past results. In this case, the control function 152 determines the priority order of the candidate drugs by making the priority of the first candidate drug higher than that of the second candidate drug and ranking the priorities, and the presentation function 153 presents the priority order in association with the information representing the inter-gene relevance. At this time, the presentation function 153 presents that there are side effects in the second candidate drug.

[0124] Note that each component of each device illustrated in this embodiment is conceptually functional and does not necessarily have to be physically configured as shown in the figure. That is, the specific form of the distribution and integration of each device is not limited to that shown in the figure, and all or part of it can be functionally or physically distributed and integrated in any unit according to various loads, usage situations, etc. Furthermore, each processing function performed by each device can be realized in whole or in any part by a CPU and a program analyzed and executed by the CPU, or can be realized as hardware by wired logic.

[0125] Also, the method described in this embodiment can be realized by executing a pre-prepared program on a computer such as a personal computer or a workstation. This program can be distributed via a network such as the Internet. Also, this program can be recorded on a non-transitory recording medium readable by a computer such as a hard disk, a flexible disk (FD), a CD-ROM, an MO, a DVD, etc., and can also be executed by being read from the recording medium by the computer.

[0126] According to at least one embodiment described above, treatment that meets the patient's desires can be proposed.

[0127] Although several embodiments have been described, these embodiments are presented as examples and are not intended to limit the scope of the invention. These embodiments can be implemented in various other forms, and various omissions, replacements, changes, and combinations of embodiments can be made without departing from the gist of the invention. These embodiments and their modifications are included in the scope and gist of the invention, and are also included in the invention described in the claims and its equivalent scope.

Description of Reference Numerals

[0128] 100 Medical information processing device 151 Acquisition function 152 Control function 153 represents a control function

Claims

1. An acquisition unit that acquires, from a gene database storing information on therapeutic agents for gene mutations associated with a disease and the effects of the therapeutic agents for each disease, a candidate agent that is a therapeutic agent for a gene mutation associated with a disease of a patient acquired by a gene testing device and the effect of the candidate agent, and acquires, as gene therapy information, information in which the acquired candidate agent and the effect of the candidate agent are associated with the supplementary information of the candidate agent; A control unit that determines the priority order of the candidate agents based on the effects and supplementary information of the candidate agents included in the gene therapy information and the patient information on the patient acquired from the patient; A presentation unit that presents the priority order in association with information representing the relevance between genes; Comprising: The patient information includes the budget of the patient; The supplementary information includes the drug price of the candidate agent; The control unit changes the priority based on the effect of the candidate agent based on the drug price of the candidate agent and the budget of the patient, and determines the priority order. A medical information processing device.

2. An acquisition unit that acquires, from a gene database storing information on therapeutic agents for gene mutations associated with a disease and the effects of the therapeutic agents for each disease, a candidate agent that is a therapeutic agent for a gene mutation associated with a disease of a patient acquired by a gene testing device and the effect of the candidate agent, and acquires, as gene therapy information, information in which the acquired candidate agent and the effect of the candidate agent are associated with the supplementary information of the candidate agent; A control unit that determines the priority order of the candidate agents based on the effects and supplementary information of the candidate agents included in the gene therapy information and the patient information on the patient acquired from the patient; A presentation unit that presents the priority order in association with information representing the relevance between genes; Comprising: The patient information includes information on the insurance policy in which the patient is enrolled; The supplementary information includes information on the insurance for which the candidate agent is applicable; The control unit changes the priority based on the effect of the candidate agent based on the information on the insurance and the information on the insurance policy in which the patient is enrolled, and determines the priority order. A medical information processing device.

3. An acquisition unit that acquires, from a gene database storing information on therapeutic agents for gene mutations associated with a disease and the effects of the therapeutic agents for each disease, a candidate agent that is a therapeutic agent for a gene mutation associated with the disease of a patient acquired by a gene testing device and the effect of the candidate agent, and acquires, as gene therapy information, information in which the acquired candidate agent and the effect of the candidate agent are associated with the supplementary information of the candidate agent. A control unit that determines the priority order of the candidate agents based on the effect of the candidate agents included in the gene therapy information and the supplementary information, and the patient information regarding the patient acquired from the patient. A presentation unit that presents the priority order in association with information representing the relevance between genes. Comprising The patient information includes the budget of the patient. The supplementary information includes information on whether the candidate agent is an investigational drug. When the candidate agent is the investigational drug, it further includes the cost required for the clinical trial. The control unit changes the priority based on the effect of the candidate agent based on information on whether the candidate agent is an investigational drug, the cost required for the clinical trial, and the budget of the patient, and determines the priority order. Medical information processing device.

4. An acquisition unit that acquires, from a gene database storing information on therapeutic agents for gene mutations associated with a disease and the effects of the therapeutic agents for each disease, a candidate agent that is a therapeutic agent for a gene mutation associated with the disease of a patient acquired by a gene testing device and the effect of the candidate agent, and acquires, as gene therapy information, information in which the acquired candidate agent and the effect of the candidate agent are associated with the supplementary information of the candidate agent. A control unit that determines the priority order of the candidate agents based on the effect of the candidate agents included in the gene therapy information and the supplementary information, and the patient information regarding the patient acquired from the patient. A presentation unit that presents the priority order in association with information representing the relevance between genes. Comprising The patient information includes information on the living level desired by the patient. The supplementary information includes information on the side effects of the candidate agent. The control unit changes the priority based on the effect of the candidate agent based on the information on the side effects of the candidate agent and the information on the living level of the patient, and determines the priority order. Medical information processing device.

5. From a gene database storing information on therapeutic agents for gene mutations associated with diseases and the effects of the therapeutic agents for each disease, a candidate agent that is a therapeutic agent for a gene mutation associated with a patient's disease acquired by a gene testing device and the effect of the candidate agent are acquired, and information associating the acquired candidate agent and the effect of the candidate agent with the supplementary information of the candidate agent is acquired as gene therapy information, an acquisition unit A control unit that determines the priority order of the candidate agents based on the effects and supplementary information of the candidate agents included in the gene therapy information and the patient information regarding the patient acquired from the patient A presentation unit that presents the priority order in association with information representing the relevance between genes Comprising The patient information includes the patient's medication history The supplementary information includes information regarding the components included in the candidate agent The control unit changes the priority based on the effect of the candidate agent based on the information regarding the components included in the candidate agent and the patient's medication history, and determines the priority order Medical information processing device

6. From a gene database storing information on therapeutic agents for gene mutations associated with diseases and the effects of the therapeutic agents for each disease, a candidate agent that is a therapeutic agent for a gene mutation associated with a patient's disease acquired by a gene testing device and the effect of the candidate agent are acquired, and information associating the acquired candidate agent and the effect of the candidate agent with the supplementary information of the candidate agent is acquired as gene therapy information, an acquisition unit A control unit that determines the priority order of the candidate agents based on the effects and supplementary information of the candidate agents included in the gene therapy information and the patient information regarding the patient acquired from the patient A presentation unit that presents the priority order in association with information representing the relevance between genes Comprising The patient information includes the patient's budget The supplementary information further includes an adoption rate representing the rate at which the candidate agent has been adopted The control unit changes the priority based on the effect of the candidate agent based on the adoption rate of the candidate agent and the patient's budget, and determines the priority order Medical information processing device

7. The presentation unit presents, as the reason for determining the priority order, the reason based on the effects and supplementary information of the candidate agent and the patient information The medical information processing device according to any one of claims 1 to 6

8. The information representing the relevance is a correlation diagram showing the relevance between genes, The presenting unit presents the priority at the position where the candidate drug acts in the correlation diagram, The medical information processing device according to any one of claims 1 to 7.

9. The control unit receives a change in the patient information and re-determines the priority of the candidate drug based on the information for which the change has been received. The medical information processing device according to any one of claims 1 to 8.

10. The adoption rate is determined based on the frequency with which the candidate drug is selected and new findings regarding the candidate drug. The medical information processing device according to claim 6.

Images